Women diagnosed with metastatic HER2-positive breast cancer lived longer if they had surgery to remove the primary tumor in the breast, according to a study. Metastatic breast cancer is cancer that has spread to parts of the body away from the breast, such as the bones or liver. The HER2 protein sits on the surface of cancer cells and receives signals that tell the cancer to grow and spread.
Surgery was associated with higher survival rates for patients with HER2-positive HER2 stage 4 breast cancer compared with those who did not undergo surgery, according to results presented at the AACR Annual Meeting Between 20 and 30 percent of all newly diagnosed stage 4 breast cancer cases are HER2explained the study's lead author, Ross Mudgway, a medical student at the University of California, Riverside School of Medicine. This form of breast cancer once had poor outcomes, but in recent years, advances in targeted therapy, such as trastuzumab Herceptinhave led to improved survival.
When NCI-supported researchers discovered that the HER2 gene is important for breast cancer growth, this led to the development of the drug trastuzumab and other targeted treatments that have improved survival for women with HER2-positive breast cancer. For years, doctors and researchers have noted that not all cancers are alike. But for other patients, their tumors grow rapidly and spread like wildfire.
Breast cancer is not a single disease. When diagnosing breast cancer, one of the first steps is identifying what type you have. The breast cancer type provides key information about how the cancer may behave.
As previously reported, the strategy does not worsen two-year overall survival but significantly shortens progression-free survival. The phase II trial randomly allocated patients to trastuzumab plus pertuzumab alone versus trastuzumab plus pertuzumab combined with chemotherapy until progression. After progression, both groups received T-DM1 as second line therapy.
HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 HER2which promotes the growth of cancer cells. In about 1 of every 5 breast cancers, the cancer cells have a gene mutation that makes an excess of the HER2 protein. HER2-positive breast cancers tend to be more aggressive than other types of breast cancer.
However, this page has some great information as well. These are all related terms because the presence of certain proteins is what makes a tumor more receptive to certain hormones. Some hormones affect growth rates, such as the hormones attracted by HER-2 proteins.
Breast cancer is heterogenous, with variable expression of the estrogen receptor erprogesterone receptor prand human epidermal growth factor receptor 2 her 2. Overexpression of her 2 is generally considered a negative prognostic feature, but whether outcomes for her 2-positive early breast cancer remain different from those for other subtypes in the era of trastuzumab-based adjuvant therapy is unknown. Trastuzumab was underutilized in this cohort.
By Alice Goodman December 10, Advertisement. Recent studies have more clearly defined the role of pertuzumab Perjeta and neratinib Nerlynx. A question currently on the table is the optimal duration of trastuzumab. A recent study Persephone demonstrated that 6 months of trastuzumab is noninferior to 1 year.